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In a recent study published in Science, Koenig et al.1 reported on
rationally engineered biparatopic nanobodies targeting the
receptor-binding domain (RBD) of the spike protein that not only
efficiently neutralize SARS-CoV-2, but additionally suppress muta-
tional escape.
Population growth, increased travel and climate change foster
epidemic and pandemic threats by (re)emerging viruses. Although
black swan events cannot be predicted, we should be prepared to
use the latest advancements in science to combat emerging
viruses. Within the past decade, we have seen several viral
outbreaks including the latest SARS-CoV-2 pandemic. Safe
effective and scalable vaccines represent undisputedly the most
cost-effective control measure. But it is not always possible to
develop and roll out a vaccine, and certain medical or age-related
conditions could exclude people from getting their jabs. Passive
immunizations by antibody-related molecules complement vac-
cines, especially in high-risk persons.
Single heavy chain type antibodies have been described for
camelids and their variable antigen-specific binding region is
termed VHH domain or nanobody. This binding region contains
three enlarged complementarity-determining regions (CDRs),
providing an expanded antigen-interacting surface, which has a
rather convex paratope making it well-suited for binding epitopes
that are inaccessible for IgG. Nanobodies are easy to manufacture
using prokaryotic expression systems, have an enhanced thermal-
and conformational stability, efficiently refold, retain their binding
characteristics and induce only a low response from the human
immune system, which makes them attractive for biomedical
applications.2 Koenig et al. immunized one alpaca and one llama
with the RBD of SARS-CoV-2 as well as formalin-inactivated SARS-
CoV-2 to generate SARS-CoV-2-neutralizing single-chain antibo-
dies. Most neutralizing antibodies against SARS-CoV-2 target the
trimeric spike (S) protein catalyzing the fusion between host and
viral membranes.3 The S protein consists of the subunits S2,
anchored in the virus envelope, and S1 comprising the N-terminal
domain (NTD) and the RBD harboring the receptor-binding motif
(RBM) that interacts with the dimeric ACE24 (Fig. 1a). Immunization
of different animal species allowed tapping into different antibody
repertoires, increasing the likelihood to fish out different binders.
They identified 10 RBD-specific antibodies by enzyme-linked
immunosorbent assay, including four nanobodies (VHHs E, U, V,
and W) with effective neutralizing capacity as shown by in vitro
assays employing SARS-CoV-2 pseudotyped vesicular stomatitis
virus. The llama-derived nanobody VHH E bound to a different
epitope than the three alpaca-derived nanobodies VHHs U, V, and
W, as shown by surface plasmon resonance-based binding
competition assays (Fig. 1b). Subsequently, the detailed binding
epitopes of the four VHHs with the RBD were revealed using X-ray
crystallography. This way, the authors were able to pinpoint not
only the different binding epitope residues, but also to predict
their competing epitopes with the ACE2 receptor and compare
the four nanobodies to other already published neutralizing
binders. Flow cytometry-based competition assays employing
ACE2 expressing HEK 293T cells confirmed the predicted
competition ability of the nanobodies. The involvement of VHHs’
individual CDRs towards their binding epitopes within the RBD
was mapped and it was shown that glycosylation of RBD’s amino
acids impacted binding.
The trimeric spike S2 subunit can exist in different conforma-
tional states; all RBD down (three-down), individual RBDs up, and
all RBDs up (three-up)5, the latter is the least populated
conformation. Binding to ACE2 requires at least one up
conformation and triggers the fusion events (Fig. 1a). In order to
decipher possible conformational changes induced by the
nanobodies VHH E and V, cryo-electron microscopy was used in
combination with a stabilized engineered spike to monitor
conformational consequences resulting from binding. Interest-
ingly, VHH E bound to all RBDs in the three-up conformation,
whereas VHH V bound to the two-up conformation (Fig. 1b). Next,
it was shown that the VHH E and V triggered the fusion machinery.
Therefore, HEK 293 cells that can be induced to express the SARS-
CoV-2 spike protein on the surface and labeled with green or red
fluorescent proteins were mixed with and without the nanobodies
allowing visualization of cell fusion induction by the VHHs E, U,
and V. In contrast, the fusion of fluorescent HEK 293 cells
expressing ACE2 or SARS-CoV-2 spike was reduced to 50% in the
presence of VHH E, confirming its neutralization capacity. As
expected, the neutralizing capacity of combinations of nanobo-
dies targeting different RBD epitopes (E-V, E-U, E-W) was
enhanced, whereas the capacity of combinations targeting the
same epitope was additive. Subsequently, multivalent nanobodies
targeting different RBD epitopes linked by flexible linkers were
produced and the biparatopic nanobodies resulted in much better
binding and neutralization capacity. Interestingly, the inclusion of
VHH E in the biparatopic nanobody VHH VE resulted in the
occupation of all six binding sites in the three-up conformation
(Fig. 1b). Multimerization of individual VHHs resulted in enhanced
affinity and up to 100-fold neutralization activity. Afterward, the
authors showed in a series of elegant experiments that the
different nanobodies neutralized by different mechanisms includ-
ing different affinities for ligands and/or secondary proteolytic
processing by proteases. Finally, they tested mutual escape, an
important test given the current emergence of mutants and their
possible implication in vaccine efficacy. They clearly showed that
the biparatopic VHHs EV and VE were superior to VVH E+U, E+V
as well as E+W in preventing mutual escape, rounding up this
nice piece of work (Fig. 1b). As in vitro data do not necessarily
translate into in vivo data, the engineered antibodies await their
Received: 23 March 2021 Revised: 15 April 2021 Accepted: 29 April 2021
1Institute of Veterinary Bacteriology, Department of Infectious Diseases and Pathobiology, University of Bern, Bern, Switzerland
Correspondence: Joerg Jores (joerg.jores@vetsuisse.unibe.ch)
www.nature.com/sigtransSignal Transduction and Targeted Therapy













functional testing using in vivo models. Although several
nanobodies have been reported mainly based on synthetic
libraries, the stability of nanobodies and the ease of production
gives the nanobodies developed a good chance to turn into a
viable commercial product to combat SARS-CoV-2 infections. In
summary, Koenig et al. performed an impressive study, reporting
on the rational engineering of nanobodies on the basis of well-
characterized binding properties and architecture in combination
with insight into the mechanistic mode of action related to spike’s
ability to trigger fusion. This paper provides a good example of
translating basic research into the development of therapeutic
binders for a pandemic pathogen.
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Fig. 1 Cartoon showing the rational engineering of nanobodies. a The spike protein consisting of the S1 and S2 subunits. The N-terminal
domain (NTD) and the receptor-binding domain (RBD) of the S1 unit during the process of binding to the angiotensin-converting enzyme 2
(ACE2) receptor are displayed (left to right). The ACE2 receptor can only bind to RBD in the up position, the binding of ACE2 triggers the fusion
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